Seeking Alpha
25 Sept 2026, 20:00 UTC · 6w ago
Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement
Impact · against what's priced in
Prime Medicine's current valuation depends on the execution of its prime editing pipeline, with the BLA timeline for PM359 and clinical data for PM577a/PM647 acting as the primary value drivers for 2027. While the outlook is positive, the lack of near-term catalysts suggests the stock may trade sideways until these milestones are reached.
- PRME+0.50
No priced-in read yet
- In context
The target BLA submission for PM359 in 1H 2027 and expected 2027 clinical data for PM577a and PM647 establish a clear commercialization horizon and data catalyst timeline.
Read from the article alone
Search tags
